ClinicalTrials.gg
CompletedNCT01139580Updated Jan 18, 2017Results posted

The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis

A Phase 3 interventional study of Calcipotriene Foam and Vehicle Foam in Psoriasis, sponsored by Stiefel, a GSK Company. Completed at 26 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-01-18.

Sponsored by Stiefel, a GSK Company (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
363
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies in Psoriasis by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Psoriasis · GlaxoSmithKline.

Enrollment
Largest of 25
363 · median 40
Started
2010
with 1 other
Phase 3
4 of 26
none open now
Registered
11th of 26
by date

Among the 26 studies in Psoriasis by GlaxoSmithKline, this one has the largest enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2010, is one of 4 in phase 3, and was the 11th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

None of the 26 studies in Psoriasis by GlaxoSmithKline is open now. The open studies under Psoriasis, anywhere →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies in Psoriasis by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to determine the safety and effectiveness in the treatment of psoriasis on the scalp and on the body.

Read the detailed description

The study subjects must have moderate psoriasis of the body and scalp with an ISGA of 3 at baseline. In addition, the subjects must have an evaluable target lesion of at least 2 cm² on the body with a score of 2 or 3 for erythema, scaling and plaque. All subjects will apply Calcipotriene Foam, 0.005% or vehicle foam topically twice a day (am and pm) to all psoriatic lesions on the body and scalp. Study visits will occur at baseline (day 1) and at weeks 1, 2, 4, and 8.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Plaque Psoriasis
  • Psoriasis
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of understanding and willing to provide signed and dated written voluntary (and any local or national authorization requirements) before any protocol-specific procedures are performed.
  • Male or female subjects at least 12 years old and in good general health.
  • Able to complete the study and to comply with study instructions.
  • Moderate plaque-type psoriasis on the body (excluding the scalp and face) defined as:

    • Plaque-type psoriasis involving 3% to 10% of total body surface area (BSA).
    • An Investigator's Static Global Assessment (ISGA) score of 3 at Baseline.
    • Identification of a target lesion (>2 cm²) on the trunk or extremities with a score of 2 or 3 (0-5 scale) for erythema, scaling and plaque thickness. Lesions on the palms/soles, knees, elbow, and intertriginous areas should not be used as the target lesion site.
  • Involvement of at least 10% of the total scalp surface area with clinical signs (erythema, thickness, and scaliness) rated as moderate (3) based on the ISGA.
  • Negative urine pregnancy test for females of . • Sexually active females of childbearing potential participating in the study must agree to use a medically acceptable method of while receiving protocol-assigned product. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are fewer than 2 years from their last menses.

Exclusion criteria

Exclusion Criteria:

  • Any subject who has participated in any previous calcipotriene foam clinical.
  • Female who is pregnant, trying to become pregnant, or breastfeeding.
  • Known allergy or other adverse reaction to calcipotriene or other vitamin D analogs; or to any component of the formulations.
  • History of hypercalcemia or of vitamin D toxicity.
  • Other serious skin disorder or any chronic medical condition that is not well-controlled.
  • Use of nonbiologic systemic anti-psoriatic therapy (eg, , psoralen combined with exposure to ultraviolet light A [PUVA], ultraviolet light B [UVB], retinoids, methotrexate, cyclosporine, other agents) within 4 weeks prior to enrollment.
  • Systemic treatment with biological therapies (marketed or not marketed) with a possible effect on psoriasis within 4 weeks (etanercept), 2 months (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 half-lives (whichever is longer) for experimental products prior to randomization.
  • Use of topical therapies that have a known beneficial effect on psoriasis, including but not limited to corticosteroids, retinoids, Vitamin D derivatives, coal tar, or anthralin, within 2 weeks prior to enrollment.
  • Systemic medications for other medical conditions that are known to affect psoriasis (eg, lithium, beta adrenergic blockers) within 4 weeks prior to enrollment.
  • Use of any investigational product within 4 weeks prior to enrollment, currently participating in another clinical trial, or plans to receive an investigational product during the study.
  • Current drug or alcohol abuse (drug screening not required).
  • Has a history of any immuno-compromizing disease.
  • Any other condition that, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study.
  • Employees of the investigator; study center; or Stiefel, a GSK company involved in the study; or an immediate family member (eg, partner, offspring, parents, siblings or sibling's offspring) of an employee involved in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
363 participants (actual)

Study arms

  • Experimental
    Calcipotriene Foam

    Calcipotriene Foam 0.005%,

    Drug: Calcipotriene Foam

  • Placebo comparator
    Vehicle Foam

    Vehicle Foam

    Drug: Vehicle Foam

Interventions

  • DrugCalcipotriene Foam

    Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group

  • DrugVehicle Foam

    Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group

06

What researchers measure

Primary outcomes

  1. Number of Participants With an Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using the Failure Method

    The investigator assessed participants with scalp psoriasis using the ISGA, scored as (as a visual average of lesions): 0, absence of disease; 1, very mild disease, lesions (L) with minimum erythema; 2, mild disease, L with light-red coloration, slight thickness, and fine, thin scale layer; 3, moderate disease, L with red coloration, moderate thickness, and a moderate scaled layer; 4, severe disease, L with red coloration, severe thickness, and a severe coarse, thick scale layer; 5, very severe disease, L with red coloration, very severe thickness, and a very severe, coarse, thick scale layer.

    Time frame: Week 8

  2. Number of Participants With an ISGA Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using Last Observation Carried Forward (LOCF)

    The investigator assessed participants with scalp psoriasis using the ISGA, scored as (as a visual average of lesions): 0, absence of disease; 1, very mild disease, lesions (L) with minimum erythema; 2, mild disease, L with light-red coloration, slight thickness, and fine, thin scale layer; 3, moderate disease, L with red coloration, moderate thickness, and a moderate scaled layer; 4, severe disease, L with red coloration, severe thickness, and a severe coarse, thick scale layer; 5, very severe disease, L with red coloration, very severe thickness, and a very severe, coarse, thick scale layer.

    Time frame: Week 8

Secondary outcomes

  1. Number of Participants With a Target Lesion Score of 0 or 1 for Erythema and at Least a 2 Grade Improvement From Baseline at Week 8

    Erythema is redness of the skin, caused by increased blood flow in the capillaries in the lower layers of the skin. The investigator assessed participants with erythema at target lesions using the psoriasis grading scale for target lesions (PGSTL). PGSTL scores: 0, no evidence of erythema, hyperpigmentation may be present; 1, faint erythema; 2, light-red coloration; 3, moderate red coloration; 4, bright-red coloration; 5, dusky to deep red coloration.

    Time frame: Baseline and Week 8

  2. Number of Participants With a Target Lesion Score of 0 or 1 for Scaling and at Least a 2 Grade Improvement From Baseline at Week 8

    Scaling of the skin is the loss of the outer layer of the epidermis in scale-like flakes. The investigator assessed participants with scaling at target lesions using the psoriasis grading scale for target lesions (PGSTL). PGSTL scores: 0, no evidence of scaling; 1, minimal, occasional fine scale over less than 5% of the lesion; 2, mild, fine scales predominate; 3, moderate, coarse scales predominate; 4 marked, thick non-tenacious scale predominates; 5 severe, very thick tenacious scale predominates.

    Time frame: Baseline and Week 8

  3. Number of Participants With a Target Lesion Score of 0 or 1 for Plaque Thickness at Week 8

    Psoriasis is a noncontagious skin disorder, most often appearing as inflamed, thickened skin covered with silvery white scales on the scalp, trunk, and limbs. The investigator assessed participants with plaque thickness at target lesions using the PGSTL scores: 0, no elevation over normal skin; 1, possible but difficult to ascertain whether there is a slight elevation above normal skin; 2, slight but definite elevation, edges are indistinct or sloped; 3, moderate elevation with rough or sloped edges; 4, marked elevation with hard or sharp edges; 5, very marked elevation with hard sharp edges.

    Time frame: Baseline and Week 8

  4. Number of Participants With an ISGA Score of Clear (0) or Almost Clear (1) for Body Involvement at Week 8

    The investigator assessed participants with psoriasis with body involvement using the ISGA, scored as: 0, clear, minor residual discoloration, no erythema, scaling, or plaque thickness; 1, almost clear, occasional fine scale, faint erythema, and barely perceptible plaque thickness; 2, mild, fine scales predominate with light-red coloration and mild plaque thickness; 3, moderate, coarse scales predominate with moderate red coloration and plaque thickness; 4 severe, thick tenacious scale predominates with deep red coloration and severe plaque thickness. Scores are a visual average of lesions.

    Time frame: Week 8

07

Results

Posted Sep 23, 2011

Participant flow

Participant flow — Overall Study
MilestoneCalcipotriene FoamVehicle Foam
Started181182
Completed158164
Not completed2318
Withdrew: Adverse event54
Withdrew: Lost to follow-up91
Withdrew: Lack of efficacy02
Withdrew: Withdrawal by subject69
Withdrew: Used excluded medicine after enrollment10
Withdrew: Did not meet exclusion criteria10
Withdrew: Misrandomized10
Withdrew: Beginning study exclusion treatment01
Withdrew: Participant randomization in error01

Outcome measures

PrimaryNumber of Participants With an Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using the Failure Method

The investigator assessed participants with scalp psoriasis using the ISGA, scored as (as a visual average of lesions): 0, absence of disease; 1, very mild disease, lesions (L) with minimum erythema; 2, mild disease, L with light-red coloration, slight thickness, and fine, thin scale layer; 3, moderate disease, L with red coloration, moderate thickness, and a moderate scaled layer; 4, severe disease, L with red coloration, severe thickness, and a severe coarse, thick scale layer; 5, very severe disease, L with red coloration, very severe thickness, and a very severe, coarse, thick scale layer.

Time frame:
Week 8
Reported as:
Number · participants
Number of Participants With an Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using the Failure Method
participantsCalcipotriene FoamVehicle Foam
Number of Participants With an Investigator's Static Global Assessment (ISGA) Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using the Failure Method7444
Statistical analysis
  • Calcipotriene Foam vs Vehicle Foam · Cochran-Mantel-Haenszel · p = <0.001
SecondaryNumber of Participants With a Target Lesion Score of 0 or 1 for Erythema and at Least a 2 Grade Improvement From Baseline at Week 8

Erythema is redness of the skin, caused by increased blood flow in the capillaries in the lower layers of the skin. The investigator assessed participants with erythema at target lesions using the psoriasis grading scale for target lesions (PGSTL). PGSTL scores: 0, no evidence of erythema, hyperpigmentation may be present; 1, faint erythema; 2, light-red coloration; 3, moderate red coloration; 4, bright-red coloration; 5, dusky to deep red coloration.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Number of Participants With a Target Lesion Score of 0 or 1 for Erythema and at Least a 2 Grade Improvement From Baseline at Week 8
participantsCalcipotriene FoamVehicle Foam
Number of Participants With a Target Lesion Score of 0 or 1 for Erythema and at Least a 2 Grade Improvement From Baseline at Week 84230
SecondaryNumber of Participants With a Target Lesion Score of 0 or 1 for Scaling and at Least a 2 Grade Improvement From Baseline at Week 8

Scaling of the skin is the loss of the outer layer of the epidermis in scale-like flakes. The investigator assessed participants with scaling at target lesions using the psoriasis grading scale for target lesions (PGSTL). PGSTL scores: 0, no evidence of scaling; 1, minimal, occasional fine scale over less than 5% of the lesion; 2, mild, fine scales predominate; 3, moderate, coarse scales predominate; 4 marked, thick non-tenacious scale predominates; 5 severe, very thick tenacious scale predominates.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Number of Participants With a Target Lesion Score of 0 or 1 for Scaling and at Least a 2 Grade Improvement From Baseline at Week 8
participantsCalcipotriene FoamVehicle Foam
Number of Participants With a Target Lesion Score of 0 or 1 for Scaling and at Least a 2 Grade Improvement From Baseline at Week 85338
PrimaryNumber of Participants With an ISGA Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using Last Observation Carried Forward (LOCF)

The investigator assessed participants with scalp psoriasis using the ISGA, scored as (as a visual average of lesions): 0, absence of disease; 1, very mild disease, lesions (L) with minimum erythema; 2, mild disease, L with light-red coloration, slight thickness, and fine, thin scale layer; 3, moderate disease, L with red coloration, moderate thickness, and a moderate scaled layer; 4, severe disease, L with red coloration, severe thickness, and a severe coarse, thick scale layer; 5, very severe disease, L with red coloration, very severe thickness, and a very severe, coarse, thick scale layer.

Time frame:
Week 8
Reported as:
Number · participants
Number of Participants With an ISGA Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using Last Observation Carried Forward (LOCF)
participantsCalcipotriene FoamVehicle Foam
Number of Participants With an ISGA Score of Clear (0) or Almost Clear (1) for Scalp Involvement at Week 8 Using Last Observation Carried Forward (LOCF)7545
Statistical analysis
  • Calcipotriene Foam vs Vehicle Foam · Cochran-Mantel-Haenszel · p = 0.001
SecondaryNumber of Participants With a Target Lesion Score of 0 or 1 for Plaque Thickness at Week 8

Psoriasis is a noncontagious skin disorder, most often appearing as inflamed, thickened skin covered with silvery white scales on the scalp, trunk, and limbs. The investigator assessed participants with plaque thickness at target lesions using the PGSTL scores: 0, no elevation over normal skin; 1, possible but difficult to ascertain whether there is a slight elevation above normal skin; 2, slight but definite elevation, edges are indistinct or sloped; 3, moderate elevation with rough or sloped edges; 4, marked elevation with hard or sharp edges; 5, very marked elevation with hard sharp edges.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Number of Participants With a Target Lesion Score of 0 or 1 for Plaque Thickness at Week 8
participantsCalcipotriene FoamVehicle Foam
Number of Participants With a Target Lesion Score of 0 or 1 for Plaque Thickness at Week 86753
SecondaryNumber of Participants With an ISGA Score of Clear (0) or Almost Clear (1) for Body Involvement at Week 8

The investigator assessed participants with psoriasis with body involvement using the ISGA, scored as: 0, clear, minor residual discoloration, no erythema, scaling, or plaque thickness; 1, almost clear, occasional fine scale, faint erythema, and barely perceptible plaque thickness; 2, mild, fine scales predominate with light-red coloration and mild plaque thickness; 3, moderate, coarse scales predominate with moderate red coloration and plaque thickness; 4 severe, thick tenacious scale predominates with deep red coloration and severe plaque thickness. Scores are a visual average of lesions.

Time frame:
Week 8
Reported as:
Number · participants
Number of Participants With an ISGA Score of Clear (0) or Almost Clear (1) for Body Involvement at Week 8
participantsCalcipotriene FoamVehicle Foam
Failure method3228
LOCF3328

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Calcipotriene Foam—1/181 (0.6%)25/181 (13.8%)
Vehicle Foam—3/182 (1.6%)17/182 (9.3%)
Most frequent serious events
Most frequent serious events
EventCalcipotriene FoamVehicle Foam
Multiple fracturesInjury, poisoning and procedural complications1/1810/182
Chest discomfortGeneral disorders0/1811/182
Cholecystitis acuteHepatobiliary disorders0/1811/182
Alcohol abusePsychiatric disorders0/1811/182
Most frequent other events
Most frequent other events
EventCalcipotriene FoamVehicle Foam
Application site painGeneral disorders8/1815/182
Application site pruritusGeneral disorders7/1817/182
Application site erythemaGeneral disorders5/1810/182
ErythemaSkin and subcutaneous tissue disorders5/1810/182
NasopharyngitisInfections and infestations0/1815/182
Application site dermatitisGeneral disorders4/1810/182
Skin burning sensationSkin and subcutaneous tissue disorders4/1810/182
Upper respiratory tract infectionInfections and infestations0/1814/182

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Calcipotriene FoamVehicle FoamTotal
Mean45.9 ± 15.344.4 ± 15.545.2 ± 15.4
Gender
Gender(Participants)Calcipotriene FoamVehicle FoamTotal
Female6976145
Male112106218
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Calcipotriene FoamVehicle FoamTotal
American Indian or Alaska Native202
Asian639
Black151833
Multiracial112
Native Hawaiian/Other Pacific Islander000
White156160316
Missing101
08

Study locations

26 sites
  • Genova Clinical Research
    Tucson, Arizona 85791, United States
  • Therapeutics Clinical Research Center, Inc.
    San Diego, California 92123, United States
  • Cherry Creek Research, Inc.
    Denver, Colorado 80209, United States
  • Miami Dermatology Research Institute LLC
    North Miami Beach, Florida 33169, United States
  • MedaPhase, Inc.
    Newnan, Georgia 30263, United States
  • Gwinnett Clinical Research Center, Inc.
    Snellville, Georgia 30078, United States
  • Dermatology Specialists
    Louisville, Kentucky 40202, United States
  • DermResearch, PLLC
    Louisville, Kentucky 40217, United States
  • Henry Ford Medical Center
    Detroit, Michigan 48202, United States
  • Grekin Skin Institute
    Warren, Michigan 48088, United States
  • Minnesota Clinical Study Center
    Fridley, Minnesota 55432, United States
  • Central Dermatology PC
    St. Louis, Missouri 63117, United States
  • Mt. Sinai School of Medicine Div. Dermatologic & Cosmetic Surgery
    New York, New York 10029, United States
  • Dermatology Associates of Rochester, PC
    Rochester, New York 14623, United States
  • Dermatology Consulting Services
    High Point, North Carolina 27262, United States
  • Wake Forest University Health Sciences Department of Dermatology
    Winston-Salem, North Carolina 27157, United States
  • Group Health Associates
    Cincinnatti, Ohio 45220, United States
  • Oregon Medical
    Portland, Oregon 97223, United States
  • Coastal Carolina Research Center
    Mt. Pleasant, South Carolina 29464, United States
  • The Skin Wellness Center, PC
    Knoxville, Tennessee 37922, United States
  • Tennessee Clinical Research
    Nashville, Tennessee 37215, United States
  • DermReserach, Inc.
    Austin, Texas 78759, United States
  • Suzanne Bruce and Associates, PA
    Houston, Texas 77056, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Dermatology Research Center, Inc.
    Salt Lake City, Utah 84124, United States
  • Education and Research Foundation
    Lynchburg, Virginia 24501, United States
09

References and documents

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2011, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2010
First posted
Jun 8, 2010
Start
May 2010
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Sep 23, 2011
Last update
Jan 18, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01139580
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 8, 2010
Start date
May 2010
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Sep 23, 2011
Last update
Jan 18, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion